Table 1.

Recently finished trials of taxanes in locally advanced HNSCC and R/M HNSCC.

A. Locally Advanced HNSCC
				Patient Number	Major Adverse Event (AE)
	Trial Design	Arms	Combined Agents		AE	N (%)	Grade	Reference
	Open-label, Single-center	1	Toripalimab + Paclitaxel/Cisplatin	20	Baldness	20 (100)	1–2	[42]
	Randomized, Open-label, Multi-center	2	RT ± Docetaxel	356	Odynophagia	177 (98.9)	3–5	[43]
	Randomized, Open-label, Multi-center	2	TPF, cisplatin + RT ± Cetuximab + RT	519	Mucositis	161 (79.7)	2–3	[44]
	Randomized, Single-center	2	Cisplatin/Carboplatin, Docetaxel + Erlotinib vs. placebo	100	Fatigue	40 (77)	1–2	[45]
	Open-label, Multi-center	1	Panitumumab (Pb) + Paclitaxel, followed Bio-RT + Pb	51	Skin toxicity	29 (56.9)	3–4	[46]
	Randomized, Open-label, Multi-center	2	TPF or TPC, followed RT + Cetuximab	100	GI disorders	23 (23)	3–5	[47]
	Non-randomized, Single-center	2	Nanoparticle albumin-bound Paclitaxel, RT/Cisplatin vs. RT/Cetuximab	79	Fatigue	44 (55.7)	1–2	[48]
B. R/M HNSCC
				Patient Number	Major Adverse Event (AE)
	Trial Design	Arms	Combined Agents		AE	N (%)	Grade	Reference
	Open-label, Multi-center	1	Pembrolizumab + Paclitaxel + carboplatin	92	Neutropenia	52 (57)	1–3	[39]
	Open-label, Multi-center	1	durvalumab combined with weekly paclitaxel carboplatin	64	no disclosure			[49]
	Open-label, Single-center	1	Pembrolizumab plus docetaxel	22	Neutropenia	3 (13.6)	3–5	[41]
	Open-label, Multi-center	1	Nab-paclitaxel+ cetuximab+carboplatin	74	Neutropenia	25 (34)	3–5	[50]